A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

Table 2 Pharmacokinetic parameters for ridaforolimus following a single oral dose or multiple once daily oral dosages of 40 mg of ridaforolimus in Chinese patients with advanced or metastatic solid tumors

^†Back-transformed least-squares mean and confidence interval from a linear mixed-effect model, containing a fixed effect for day and a random effect for subject, performed on natural log-transformed values.
^‡Geometric Mean and back-transformed 95% CI for AUC_0-24hr, AUC_0-∞, C_max, and C_24hr. Harmonic Mean and jackknife SD for T1/2. Median and Range (Min, Max) for T_lag and T_max.
^*Both for Day 1 and Day 19 no samples were taken between 8 hr and 24 hr post dose. However, for some patients no concentration levels above the lower limit of quantification could be obtained until 8 hr post dose on Day 1. Consequently some PK parameters could not be calculated for these patients. In addition, Tlag was presented for all patients on Day 1.
^**Two subjects were not evaluable for PK on Day 19 due to AE-related dose reduction.

ISSN: 1756-8722